Live Breaking News & Updates on Nikolas Stoecklein
Stay updated with breaking news from Nikolas stoecklein. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CANCER-ID was a European consortium funded by the Innovative Medicines Initiative (IMI) aimed at the establishment of standard protocols for and clinical validation of blood-based biomarkers. It brought together experts from academic and clinical research, innovative Small-to-Medium sized Enterprises (SMEs), diagnostics companies and the pharmaceutical industry thus providing a unique setting for establishing clinical utility of liquid biopsies .
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE s proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins. ....
Angle PLC - Parsortix Demonstrates High Capture Rate of CTCs saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
ANGLE plc: Angle PLC - Parsortix Demonstrates High Capture Rate of CTCs Parsortix system demonstrates high capture rate of CTCs irrespective of biomarker status or phenotype GUILDFORD, SURREY / ACCESSWIRE / January 29, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce the publication of a five year programme of work undertaken by the CANCER-ID Consortium to establish the performance and technical capabilities of five circulating tumour cell (CTC) isolation platforms, in which key advantages of the Parsortix ® system were identified. The CANCER-ID consortium is supported by Europe s Innovative Medicines Initiative (IMI) and is a Europe-wide Public-Private-Partnership aimed at the establishment of standard protocols for, and clinical validation of, blood-based biomarkers in order to drive wide adoption of liquid biopsy in clinical practice and pharma services. ....